Both series yielded unique opportunities to investigate the prognostic value of the CD27−:CD27+ ratio as a surrogate of clonal T cell expansions in patients treated with regimens including lenalidomide, an IMID that requires tumor-reactive T cells to mediate its anti-MM effect25. This evidence concerns the gene CD27 and neoplasm.